MAPT and Alzheimer disease: Currently, the diagnostic tools of AD include magnetic resonance imaging (MRI), positron emission tomography (PET) imaging, and cerebrospinal fluid (CSF) biomarkers (Aβ1-42, Aβ1-42/Aβ1-40 ratio, T-tau and P-tau levels)10.